Rheumatology International

, Volume 30, Issue 12, pp 1601–1604 | Cite as

DNase1 activity in systemic lupus erythematosus patients with and without nephropathy

  • Fernando Martinez-ValleEmail author
  • Eva Balada
  • Josep Ordi-Ros
  • Segundo Bujan-Rivas
  • Agustin Sellas-Fernandez
  • Miquel Vilardell-Tarres
Original Article


The objective of the study is to determine whether the activity of DNase1 is associated to the presence of nephropathy in patients with SLE. Forty-five patients affected with SLE and renal involvement were analyzed. The type of renal involvement was type III or IV glomerulonephritis. At least two serum samples were withdrawn from each patient, one obtained in a renal flare and the other obtained in a period of clinical stability. C3 and C4 complement levels and anti-DNA antibodies were determined. DNase1 activity was measured using a radial enzyme-diffusion method. Results suggest that when comparison of DNase1 activity was established between samples obtained during a phase of active renal involvement and those obtained in the clinically stable phase, we did not find statistically significant differences. When the comparison was performed with matched samples of the same patient, DNase1 activity was lower when patients had active renal involvement than when samples were taken in clinically stable phase (21.21 μg/ml ± 16.47 vs. 25.62 μg/ml ± 18.81, p < 0.05). No difference in DNase1 activity was observed between samples positive or negative for anti-DNA antibodies. No difference in DNase1 activity was found in patients with normal or decreased levels of C3 (25.09 μg/ml ± 17.78 vs. 20.01 μg/ml ± 16.15, p = 0.073) or C4 (23.52 μm/ml ± 16.60 vs. 19.62 μg/ml ± 17.54, p = 0.060). We conclude that low DNase1 activity is associated to the active phase of type III or IV nephropathy. Therefore, it is possible that this enzyme plays an important role in the development of SLE nephropathy.


DNase1 activity Systemic lupus erythematosus Autoantibodies Nephropathy 



Systemic lupus erythematosus.


Double-stranded DNA


American College Rheumatology


Conflict of interest statement

The authors declare no conflict of interest.


  1. 1.
    Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537CrossRefPubMedGoogle Scholar
  2. 2.
    Bruneau C, Benveniste J (1979) Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J Clin Invest 64:191–198CrossRefPubMedGoogle Scholar
  3. 3.
    Brinkman K, Termaat R, Berden JH, Smeenk RJ (1990) Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol Today 11:232–234CrossRefPubMedGoogle Scholar
  4. 4.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Jedryka-Goral A, de Ramon E, Fernandez-Nebro A, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, Ingelmo M, Hughes GR (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175CrossRefGoogle Scholar
  5. 5.
    Yang LY, Chen WP, Lin CY (1994) Lupus nephritis in children—a review of 167 patients. Pediatrics 94:335–340PubMedGoogle Scholar
  6. 6.
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113–124Google Scholar
  7. 7.
    Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC (2007) Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 16:28–34CrossRefPubMedGoogle Scholar
  8. 8.
    Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, Limburg P, Gmelig-Meyling F, Kater L, Kallenberg C (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345:1595–1599CrossRefPubMedGoogle Scholar
  9. 9.
    ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33:634–643CrossRefPubMedGoogle Scholar
  10. 10.
    Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ (2000) Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 76:227–324CrossRefPubMedGoogle Scholar
  11. 11.
    Graham KL, Utz PJ (2005) Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 17:513–517CrossRefPubMedGoogle Scholar
  12. 12.
    Walport MJ (2000) Lupus, DNase and defective disposal of cellular debris. Nat Genet 25:135–136CrossRefPubMedGoogle Scholar
  13. 13.
    Koutouzov S, Jeronimo AL, Campos H, Amoura Z (2004) Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 30:529–558CrossRefPubMedGoogle Scholar
  14. 14.
    Laskowski M (1971) Deoxyribonuclease I. In: Boyer PD (ed) The enzymes, 3rd edn, vol 4. New York Academic Press, NY, pp 289–311Google Scholar
  15. 15.
    Lacks SA (1981) Deoxyribonuclease I in mammalian tissues. Specificity of inhibition by actin. J Biol Chem 256:2644–2648PubMedGoogle Scholar
  16. 16.
    Mannherz HG, Peitsch MC, Zanotti S, Paddenberg R, Polzar B (1995) A new function for an old enzyme: the role of DNase I in apoptosis. Curr Top Microbiol Immunol 198:161–174PubMedGoogle Scholar
  17. 17.
    Napirei M, Wulf S, Mannherz HG (2004) Chromatin breakdown during necrosis by serum DNase1 and the plasminogen system. Arthritis Rheum 50:1873–1883CrossRefPubMedGoogle Scholar
  18. 18.
    Martinez-Valle F, Balada E, Ordi-Ros J, Bujan-Rivas S, Sellas-Fernandez A, Vilardell-Tarres M (2009) DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 18:418–423CrossRefPubMedGoogle Scholar
  19. 19.
    Chitrabamrung S, Bannett JS, Rubin RL, Tan EM (1981) A radial diffusion assay for plasma and serum deoxyribonuclease I. Rheumatol Int 1:49–53CrossRefPubMedGoogle Scholar
  20. 20.
    Chitrabamrung S, Rubin RL, Tan EM (1981) Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1:55–60CrossRefPubMedGoogle Scholar
  21. 21.
    Macanovic M, Lachmann PJ (1997) Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol 108:220–226CrossRefPubMedGoogle Scholar
  22. 22.
    Tan EM, Schur PH, Carr RI, Kunkel HG (1966) Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 45:1732–1740CrossRefPubMedGoogle Scholar
  23. 23.
    Schur PH, Sandson J (1968) Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278:533–538CrossRefPubMedGoogle Scholar
  24. 24.
    Miniter MF, Stollar BD, Agnello V (1979) Reassessment of the clinical significance of native DNA antibodies in systemic lupus erythematosus. Arthritis Rheum 22:959–968CrossRefPubMedGoogle Scholar
  25. 25.
    Berden JH (1997) Lupus nephritis. Kidney Int 52:538–558CrossRefPubMedGoogle Scholar
  26. 26.
    Bell DA, Morrison B, VandenBygaart P (1990) Immunogenic DNA-related factors. Nucleosomes spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J Clin Invest 85:1487–1496CrossRefPubMedGoogle Scholar
  27. 27.
    Dieker JW, van der Vlag J, Berden JH (2002) Triggers for anti-chromatin autoantibody production in SLE. Lupus 11:856–864CrossRefPubMedGoogle Scholar
  28. 28.
    Licht R, Dieker JW, Jacobs CW, Tax WJ, Berden JH (2004) Decreased phagocytosis of apoptotic cells in diseased SLE mice. J Autoimmun 22:139–145CrossRefPubMedGoogle Scholar
  29. 29.
    Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR, Herrmann M (2006) Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 305:161–176CrossRefPubMedGoogle Scholar
  30. 30.
    Denny MF, Chandaroy P, Killen PD, Caricchio R, Lewis EE, Richardson BC, Lee KD, Gavalchin J, Kaplan MJ (2006) Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol 176:2095–2104PubMedGoogle Scholar
  31. 31.
    White S, Rosen A (2003) Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol 15:557–562CrossRefPubMedGoogle Scholar
  32. 32.
    Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965–975CrossRefPubMedGoogle Scholar
  33. 33.
    Peitsch MC, Irmler M, French LE, Tschopp J (1995) Genomic organisation and expression of mouse deoxyribonuclease I. Biochem Biophys Res Commun 207:62–68CrossRefPubMedGoogle Scholar
  34. 34.
    Gaipl US, Beyer TD, Heyder P, Kuenkele S, Bottcher A, Voll RE, Kalden JR, Herrmann M (2004) Cooperation between C1q and DNase I in the clearance of necrotic cell-derived chromatin. Arthritis Rheum 50:640–649CrossRefPubMedGoogle Scholar
  35. 35.
    Suzuki N, Harada T, Mizushima Y, Sakane T (1993) Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus. J Immunol 151:1128–1136PubMedGoogle Scholar
  36. 36.
    Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA (1998) Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161:4467–4471PubMedGoogle Scholar
  37. 37.
    Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86–89CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Fernando Martinez-Valle
    • 1
    Email author
  • Eva Balada
    • 1
  • Josep Ordi-Ros
    • 1
  • Segundo Bujan-Rivas
    • 1
  • Agustin Sellas-Fernandez
    • 1
  • Miquel Vilardell-Tarres
    • 1
  1. 1.Research Unit in Systemic Autoimmune Diseases, Vall d’Hebron Research InstituteHospital Vall d’HebronBarcelonaSpain

Personalised recommendations